ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2405

A Proof-of-Concept Study of an Animated, Web-Based Methotrexate Decision Aid for Patients with Rheumatoid Arthritis

Linda C. Li1, Paul M. Adam2, Catherine L. Backman3, Sydney Brooks4, Gwen A. Ellert5, Allyson Jones6, Otto Kamensek7, Cheryl Koehn8, Diane Lacaille7, Colleen Maloney7, Anne F. Townsend9, Elaine Yacyshyn10, Charlene Yousefi7 and Dawn Stacey11, 1Department of Physical Therapy, University of British Columbia, Vancouver, BC, Canada, 2Rheumatology Liaison, Mary Pack Arthritis Centre, Vancouver, BC, Canada, 3Occupational Science & Occupational Therapy, The University of British Columbia, Vancouver, BC, Canada, 4The Arthritis Society, Ontario Division, Toronto, ON, Canada, 5Health Education, Trelle Enterprises Inc, Vancouver, BC, Canada, 6Department of Physical Therapy, University of Alberta, Edmonton, AB, Canada, 7Arthritis Research Centre of Canada, Vancouver, BC, Canada, 8Arthritis Consumer Experts, Vancouver, BC, Canada, 9Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, 10562 Heritage Med Rsch Ctr, University of Alberta, Edmonton, AB, Canada, 11School of Nursing, University of Ottawa, Ottawa, ON, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Education, methotrexate (MTX), patient, patient preferences, rheumatoid arthritis (RA) and self-management

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Education/Community Programs

Session Type: Abstract Submissions (ARHP)

Background/Purpose: Patient decision aids are designed to present the potential benefits and harm of treatment options, clarify individuals’ preferences, and guide discussion at a clinic visit. The majority of decision aids on arthritis treatments are in printed formats. Although informative, they tend to be less engaging for users. We applied the concept of edutainment (i.e., education that engages through entertainment) to develop a web-based decision aid called ANSWER. Designed for patients with rheumatoid arthritis (RA), ANSWER presents information on methotrexate (MTX) in print, voice recording, and animated stories created with Adobe Photoshop. The current study aims to assess the extent to which ANSWER reduces patient’s decisional conflict, and improves their medication knowledge and skills of being ‘effective healthcare consumers’. 

Methods:   We used a pre-post study design. Participants were recruited from rheumatologists’ clinics, patient groups and social networking sites (Facebook, Twitter, Craigslist, Kijiji). Eligible participants were those who: 1) had a physician diagnosis of RA, 2) had been prescribed MTX but were unsure about starting it, 3) had access to the internet. Password access to the ANSWER was provided immediately after enrollment. Participants completed a questionnaire before and within 48 hours after using the ANSWER. Outcome measures included: 1) Decisional Conflict Scale (DCS, primary outcome; 0-100, scores <25 are associated with follow-through with decisions), 2) MTX in RA Knowledge Test (MiRAK; 0-60, higher=better), and 3) Effective Consumer Scale (EC-17; 0-100, higher=better). Paired t-test was used to assess differences before and after the intervention.

Results:    30 participants were recruited between November 2010 and April 2012. The majority were women (n=23, 76.7%) with a mean age of 54.90 years (SD=14.91). 73.3% (n=22) attended/graduated from university. The median disease duration was 1 year (IRQ=0.3; 5.0), and the mean Health Assessment Questionnaire score was 1.16 (SD=0.68). The mean DCS was 49.50 (SD=23.17) pre-intervention and 21.83 (SD=24.12) post-intervention (change= -27.67, 95% CI= -15.44, -39.89; p<0.001). Before using the ANSWER, 13.3% of participants scored <25, compared to 70% after the intervention. Similar results were observed in MiRAK (pre: 30.62, SD=9.26; post: 41.67, SD=6.81; change: 11.03, 95% CI=6.73, 15.34; p<0.001), but not in EC-17 (pre: 68.24, SD=12.46; post: 72.94, SD=12.74; change: 4.71; 95% CI= -1.81, 11.22; p=0.15). After using the ANSWER, 20 participants (66.6%) were able to make a decision (14 would take MTX, 6 would decline MTX and talk to their doctor about other treatment options). 10 participants (33.3%) remained unsure about their preferred choice.

Conclusion:   Patients’ decisional conflict and MTX knowledge improved after using the ANSWER. Our results show similar changes to other studies evaluating decision aids in chronic diseases. The lack of a statistically significant change in the EC-17 might reflect the fact that it takes time to develop effective consumer attributes, such as how to find resources. Further research into the application of edutainment in developing patient decision aids and education programs is warranted.


Disclosure:

L. C. Li,
None;

P. M. Adam,
None;

C. L. Backman,
None;

S. Brooks,
None;

G. A. Ellert,
None;

A. Jones,
None;

O. Kamensek,
None;

C. Koehn,
None;

D. Lacaille,
None;

C. Maloney,
None;

A. F. Townsend,
None;

E. Yacyshyn,
None;

C. Yousefi,
None;

D. Stacey,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-proof-of-concept-study-of-an-animated-web-based-methotrexate-decision-aid-for-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology